Aster DM Healthcare reported a 10% YoY revenue increase to INR 1,197 Crore for Q2 FY26. Operating EBITDA rose by 13% YoY to INR 263 Crore. The company is progressing with its merger with Quality Care India Limited, with approvals received from shareholders and the Competition Commission of India. It’s expanding capacity, aiming for over 7,800 beds in the future.
Financial Performance
Aster DM Healthcare announced its financial results for Q2 FY26, highlighting the following:
- Revenue increased by 10% YoY to INR 1,197 Crore.
- Operating EBITDA grew by 13% YoY to INR 263 Crore, with a margin of 22.0%.
- Normalised PAT (Post NCI) increased to INR 110 Crore, a 14% YoY growth.
For the half-year ended September 30, 2025, India revenues increased by 9% YoY to INR 2,275 Crore, and Operating EBITDA grew by 17% YoY to INR 478 Crore.
Operational Highlights
Key operational achievements and strategic initiatives include:
- Kerala cluster delivered record-high performance; up 11% YoY to INR 620 Crore.
- Karnataka & Maharashtra cluster reported 10% YoY revenue growth.
- Andhra Pradesh & Telangana revenue grew 8% YoY.
- Aster Labs has successfully delivered a turnaround, with EBITDA margins expanding to 17.8% in Q2 FY26.
Strategic Developments
- Merger with Quality Care India Limited is progressing, having received approvals from shareholders and the Competition Commission of India.
- Acquired an additional 13% stake in Aster Ramesh Hospitals, increasing Aster’s stake to over 70%.
- Capacity expansion plans are underway, aiming to exceed 7,800 beds.
- Commissioned a new 264-bed hospital in Kasaragod.
Quality Care India Limited (QCIL) Performance
- Revenue grew by 15.1% YoY to INR 1,193 Crore.
- EBITDA margin (post-Ind AS) improved to 24.1% in Q2 FY26.
- ARPP grew by 10% YoY.
Expansion and Future Outlook
Aster DM Healthcare is committed to strengthening its presence in existing markets and entering new ones. An investment of around INR 2,000 Crore is planned to add over 1,700 beds in the next 3-4 years, with a focus on non-Metro / Tier-2 markets.
Source: BSE